Summary
Otitis media and rhinopharyngitis are common childhood illnesses, and are mostly treated with antibiotics. Antibiotics do not, however, prevent recurrences and can result in high treatment costs. This study analyses the cost of two treatment options for children with otitis media and rhinopharyngitis: immunoprophylaxis using a ribosomal immunostimulant (Ribomunyl®, Pierre Fabre Medicament, France) versus no immunoprophylaxis. The per-patient cost of Ribomunyl® in Austrian schillings [ÖS728 ($US1 = ÖS 12.80 at August 1997)] was found to be offset by direct savings through the prevention of acute infectious episodes. Ribosomal immunotherapy was found to be cost effective in the core analysis, in which costs of concomitant medication and out- and inpatient ENT-specialist services were not included. Based on a restricted core analysis, taking into account physician visits, antibiotics and Ribomunyl®, the net savings per patient on 6 months ranged from 7.0 to 12.0% in this most conservative estimate. The absolute savings per patient on 6 months were estimated to be between ÖS 162 and 315. Additional substantial savings could be expected from lower prescription frequencies of concomitant medication, and conservative surgical ENT-physician services, especially in cases requiring inpatient care. These savings have been evaluated and reinforce the results.
Similar content being viewed by others
References
Fiocchi A, Arancio R, Cinquepalmi P, et. al. Recurrent respiratory infections in childhood: experience with a bacterial extract plus bacterial ribosomes (Immucytal). J Int Med Res 1990; 18: 50–60
Vautel JM, Cauquil J, Perruchet AM, et al. Prevention of recurrent ear, nose, and throat infections in young children with Ribomunyl double-blind, placebo-controlled study. Curr Ther Res 1993; 6: 722–9
Blaive B, Demichelis B, Lemoigne F, et al. Éfficacite de la vaccination par extraits ribosomaux dans le traitement preventif des episodes infectieux des bronchopathies chroniques. Med Mal Infect 1982; 8: 475–9
Castel Y. Prévention des récidives infectieuses des voies respiratoires chez l’enfant par Ribomunyl comprimés. Immunol Med 1986; 14: 34–40
Cotin G, Lesbros D. Prévention des récidives infectieuses des voies respiratoires par Ribomunyl comprimés. Immunol Med 1986; 14: 28–33
Girard JP, Gumowski PI, Chavaz A, et al. Place des différentes formes de Ribomunyl dans les infections récidivantes des voies aériennes. Schweiz Med Wschr 1988; 118: 856–61
Haguenauer JP. Prévention des épisodes infectieux récidivants de la sphère ORL par Ribomunyl comprimés chez l’enfant de moins de 5 ans. Immunol Med 1987; 18: 36–9
Hüls G, Hirche H, Lindemann H. Klinische Effizienz eines neuen multibakteriellen Immuntherapeutikums (Ribomunyl) bei Kindern und Jugendlichen mit rezidivierenden respiratorischen Infekten. Jatros Padiatr 1991; 9: 3–14
Lacomme Y. Prévention par immunothérapie ribosomale des épisodes de surinfection récidivante de la sphère ORL chez l’enfant. Immunol Med 1985; 11: 73–5
Legros M. Prévention des récidives infectieuses de la sphère ORL par Ribomunyl comprimés. Immunol Med 1986; 14: 41–6
Banz K, Schwicker D, Thomas AM. Economic evaluation of immunoprophylaxis in children with recurrent ear, nose, and throat infections. Pharmaco Economics 1994; 6(5): 464–77
Bennett C, Schwarz B, Marberger M. Healthcare in Austria. JAMA 1993; 269: 2789–94
Wiener Gebietskrankenkasse. Gesamtvertrag und Honorarordnung für Vertragsärzte. Wien, 1994
Hauptverband der österreichischen Sozialversicherungsträger (ed.). Heilmittelverzeichnis. Wien, 1994
Zielhuis GA, Rach GH, van den Broek P. The natural course of otitis media with effusion in preschool children. Eur Arch Otorhinolaryngol 1990; 247: 215–21
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schwarz, B., Dangl-Neugaard, B. An Economic Analysis Using Ribosomal Immunotherapy to Treat Children with Recurrent Upper Respiratory Tract Infections. Clin. Drug Invest. 14, 206–210 (1997). https://doi.org/10.2165/00044011-199714030-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-199714030-00007